A Fortune 500 company, in conjunction with IBM Watson Health, conducted an economic evaluation to test whether our flagship digital therapeutic for insomnia, Sleepio, would lower health care costs for their employees.
Individuals who used Sleepio had 28% lower annualized total healthcare costs compared to those who did not use Sleepio — demonstrating $1,677 lower health care costs per employee that used Sleepio.
A peek inside:
Here’s our latest
The state of mental health equity
Insights from clinical experts focused on improving mental health disparities.
The State of Sleep & Mental Health
A first of its kind report comprehensively examining the impact of poor sleep and mental health on medical and pharmacy…
Using Clinical Evidence to Evaluate Digital Therapeutics for Mental Health
Benefits leaders are turning to digital therapeutics to address employee mental health, but many questions remain. How can you distinguish…
